Informace o publikaci
Bendamustine-Bortezomib-Dexamethasone is an active and well tolerated regimen in patients with relapsed or refractory multiple myeloma
| Autoři | |
|---|---|
| Rok publikování | 2014 |
| Druh | Článek v odborném periodiku |
| Časopis / Zdroj | Blood |
| Fakulta / Pracoviště MU | |
| Citace | |
| Doi | http://dx.doi.org/10.1182/blood-2013-08-521468 |
| Obor | Onkologie a hematologie |
| Klíčová slova | Bendamustine; bortezomib; dexamethasone; relapsed/refractory myeloma |
| Popis | Bendamustine with bortezomib and dexamethasone was evaluated in 79 patients with relapsed/refractory multiple myeloma. Median age was 64 (range 40-80) years and patients had a median of 2 (range 1-6) prior treatment lines. Bendamustine 70 mg/m2, day 1 and 4, bortezomib 1.3mg/m2 days 1, 4, 8, 11 intravenously, and dexamethasone 20 mg, days 1, 4, 8, and 11, q 28 days, was given for up to 8 cycles. Primary endpoint was response rate (ORR) and secondary endpoints were progression-free survival (PFS), overall survival (OS), time to response and toxicity. ORR was 60.9%, and when minor responses were included, 75.9%. Median time to response was 31 days (111 to best response). ORR rate was similar in patients previously exposed to bortezomib, lenalidomide and to both bortezomib and lenalidomide. PFS was 9.7 and OS 25.6 months. Multivariate analysis showed high LDH, >/-3 prior treatment lines and low platelet counts correlating with short survival. Grade 3/4 thrombopenia and G 3/4/5 infections were noted in 38% and 23% respectively. Grade |